company background image
1548

Genscript Biotech SEHK:1548 Stock Report

Last Price

HK$28.40

Market Cap

HK$60.3b

7D

2.5%

1Y

-20.3%

Updated

28 Jun, 2022

Data

Company Financials +
1548 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

1548 Stock Overview

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally.

Rewards

Earnings are forecast to grow 54.52% per year

Risk Analysis

No risks detected for 1548 from our risk checks.

Genscript Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genscript Biotech
Historical stock prices
Current Share PriceHK$28.40
52 Week HighHK$43.40
52 Week LowHK$17.58
Beta1.84
1 Month Change36.54%
3 Month Change8.60%
1 Year Change-20.34%
3 Year Change43.87%
5 Year Change576.19%
Change since IPO2,051.52%

Recent News & Updates

Apr 03
Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Shareholder Returns

1548HK Life SciencesHK Market
7D2.5%6.9%1.7%
1Y-20.3%-45.4%-21.2%

Return vs Industry: 1548 exceeded the Hong Kong Life Sciences industry which returned -45.4% over the past year.

Return vs Market: 1548 matched the Hong Kong Market which returned -21.2% over the past year.

Price Volatility

Is 1548's price volatile compared to industry and market?
1548 volatility
1548 Average Weekly Movement9.5%
Life Sciences Industry Average Movement9.0%
Market Average Movement6.9%
10% most volatile stocks in HK Market13.8%
10% least volatile stocks in HK Market3.4%

Stable Share Price: 1548 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 1548's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20025,258Patrick Liuhttps://www.genscript.com

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry.

Genscript Biotech Fundamentals Summary

How do Genscript Biotech's earnings and revenue compare to its market cap?
1548 fundamental statistics
Market CapUS$7.69b
Earnings (TTM)-US$347.86m
Revenue (TTM)US$511.06m

15.0x

P/S Ratio

-22.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1548 income statement (TTM)
RevenueUS$511.06m
Cost of RevenueUS$207.58m
Gross ProfitUS$303.48m
Other ExpensesUS$651.35m
Earnings-US$347.86m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin59.38%
Net Profit Margin-68.07%
Debt/Equity Ratio35.0%

How did 1548 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 1548 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1548?

Other financial metrics that can be useful for relative valuation.

1548 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13.5x
Enterprise Value/EBITDA-21.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 1548's PS Ratio compare to its peers?

1548 PS Ratio vs Peers
The above table shows the PS ratio for 1548 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8.6x
2269 WuXi Biologics (Cayman)
26.2x23.8%HK$323.4b
1521 Frontage Holdings
4.6x18.2%HK$6.9b
1873 Viva Biotech Holdings
2.2x27.7%HK$5.4b
6118 Austar Lifesciences
0.6xn/aHK$1.4b
1548 Genscript Biotech
15x46.1%HK$60.3b

Price-To-Sales vs Peers: 1548 is expensive based on its Price-To-Sales Ratio (15x) compared to the peer average (8.6x).


Price to Earnings Ratio vs Industry

How does 1548's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

Price-To-Sales vs Industry: 1548 is expensive based on its Price-To-Sales Ratio (15x) compared to the Hong Kong Life Sciences industry average (4.4x)


Price to Sales Ratio vs Fair Ratio

What is 1548's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1548 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15x
Fair PS Ratio20.7x

Price-To-Sales vs Fair Ratio: 1548 is good value based on its Price-To-Sales Ratio (15x) compared to the estimated Fair Price-To-Sales Ratio (20.7x).


Share Price vs Fair Value

What is the Fair Price of 1548 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1548's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1548's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1548's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Genscript Biotech forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


54.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1548 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: 1548 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 1548 is expected to become profitable in the next 3 years.

Revenue vs Market: 1548's revenue (46.1% per year) is forecast to grow faster than the Hong Kong market (10.3% per year).

High Growth Revenue: 1548's revenue (46.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1548's Return on Equity is forecast to be low in 3 years time (14.7%).


Discover growth companies

Past Performance

How has Genscript Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-70.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1548 is currently unprofitable.

Growing Profit Margin: 1548 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1548 is unprofitable, and losses have increased over the past 5 years at a rate of 70.5% per year.

Accelerating Growth: Unable to compare 1548's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1548 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (45.8%).


Return on Equity

High ROE: 1548 has a negative Return on Equity (-45.83%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Genscript Biotech's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 1548's short term assets ($1.6B) exceed its short term liabilities ($464.4M).

Long Term Liabilities: 1548's short term assets ($1.6B) exceed its long term liabilities ($675.4M).


Debt to Equity History and Analysis

Debt Level: 1548 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 1548's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1548 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 1548 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 44.4% each year


Discover healthy companies

Dividend

What is Genscript Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1548's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1548's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1548's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1548's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 1548 is not paying a notable dividend for the Hong Kong market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 1548 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Patrick Liu (44 yo)

1.83yrs

Tenure

US$731,000

Compensation

Dr. Zhenyu Liu, also known as Patrick, serves as the Chief Executive Officer of Genscript Biotech Corporation since August 2, 2020. He has management experience in the life science and biologics developmen...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD731.00K) is about average for companies of similar size in the Hong Kong market ($USD591.24K).

Compensation vs Earnings: Insufficient data to compare Patrick's compensation with company performance.


Leadership Team

Experienced Management: 1548's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: 1548's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1548 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genscript Biotech Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Genscript Biotech Corporation
  • Ticker: 1548
  • Exchange: SEHK
  • Founded: 2002
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$60.292b
  • Shares outstanding: 2.11b
  • Website: https://www.genscript.com

Number of Employees


Location

  • Genscript Biotech Corporation
  • Jiangning Science Park
  • No. 28, Yongxi Road
  • Nanjing
  • Jiangsu Province
  • 211100
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.